Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449397
Status:
COMPLETED
Last Update Posted:
2011-01-27
First Post:
2007-03-19
Brief Title:
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Naturalistic Prospective Single Centre Double Blinded Fixed Dose Randomised Four Week Comparison Study Investigating Efficacy Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is determine the minimal effective dose and the impact on
1 treatment outcomes at 4 12 andor 48 weeks the treatment has required to treat patients experiencing the first psychotic episode
2 the final maintenance doses
3 the use of other medications
4 the amount of changes to other antipsychotic medication
5 the number of hospitalization days
1 treatment outcomes at 4 12 andor 48 weeks the treatment has required to treat patients experiencing the first psychotic episode
2 the final maintenance doses
3 the use of other medications
4 the amount of changes to other antipsychotic medication
5 the number of hospitalization days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None